- Home
- VSTM vs OMER Comparison
VSTM vs OMER Comparison
Compare VSTM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- OMER
- Stock Information
- Founded
- VSTM 2010
- OMER 1994
- Country
- VSTM United States
- OMER United States
- Employees
- VSTM N/A
- OMER N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- OMER Health Care
- Exchange
- VSTM Nasdaq
- OMER Nasdaq
- Market Cap
- VSTM 493.6M
- OMER 513.8M
- IPO Year
- VSTM 2012
- OMER 2009
- Fundamental
- Price
- VSTM $8.85
- OMER $7.80
- Analyst Decision
- VSTM Strong Buy
- OMER Strong Buy
- Analyst Count
- VSTM 9
- OMER 6
- Target Price
- VSTM $13.38
- OMER $27.50
- AVG Volume (30 Days)
- VSTM 2.2M
- OMER 8.2M
- Earning Date
- VSTM 11-04-2025
- OMER 11-12-2025
- Dividend Yield
- VSTM N/A
- OMER N/A
- EPS Growth
- VSTM N/A
- OMER N/A
- EPS
- VSTM N/A
- OMER N/A
- Revenue
- VSTM $2,137,000.00
- OMER N/A
- Revenue This Year
- VSTM $79.32
- OMER N/A
- Revenue Next Year
- VSTM $413.52
- OMER N/A
- P/E Ratio
- VSTM N/A
- OMER N/A
- Revenue Growth
- VSTM N/A
- OMER N/A
- 52 Week Low
- VSTM $3.19
- OMER $2.95
- 52 Week High
- VSTM $11.25
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- VSTM 51.64
- OMER 63.02
- Support Level
- VSTM $7.60
- OMER $7.44
- Resistance Level
- VSTM $9.16
- OMER $8.05
- Average True Range (ATR)
- VSTM 0.66
- OMER 0.73
- MACD
- VSTM -0.02
- OMER 0.04
- Stochastic Oscillator
- VSTM 61.99
- OMER 47.17
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.